| Bioactivity | TDRL-551 is a potent replication protein A (RPA) inhibitor (IC50=18 µM). TDRL-551 inhibits RPA-DNA interaction and increases the efficacy of Platinum (Pt)-based chemotherapy in lung and ovarian cancer. RPA plays essential roles in both nucleotide excision repair (NER) and homologous recombination (HR), along with its role in DNA replication and DNA damage checkpoint activation[1]. | ||||||||||||
| Name | TDRL-551 | ||||||||||||
| CAS | 1644626-43-6 | ||||||||||||
| Formula | C25H23ClIN3O4 | ||||||||||||
| Molar Mass | 591.83 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Mishra AK, et al. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015;93(1):25-33. |
TDRL-551
CAS: 1644626-43-6 F: C25H23ClIN3O4 W: 591.83
TDRL-551 is a potent replication protein A (RPA) inhibitor (IC50=18 µM). TDRL-551 inhibits RPA-DNA interaction and incr
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.